Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Summary
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.
Timeline
- Start
- 2020-11-10
- Primary completion
- 2023-05-17
- Completion
- 2024-10-29
Outcome
Outcome not reported
Stopped (Business): “Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | — | Oral |
| Subject | Binimetinib | Small molecule | — | Oral |
| Subject | Encorafenib | Small molecule | — | Oral |
| Subject | SEA-TGT | Unknown | — | Intravenous |
| Subject | Sasanlimab | Monoclonal antibody | — | Subcutaneous |